Stockreport

Revolution Medicines to Showcase Progress Across RAS(ON) Targeted Oncology Pipeline with Multiple Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting [...

Revolution Medicines, Inc.  (RVMD) 
PDF clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that nine oral and poster presentations highlighting adva [Read more]